» Articles » PMID: 24283360

MicroRNA-143 Regulates Collagen Type III Expression in Stromal Fibroblasts of Scirrhous Type Gastric Cancer

Overview
Journal Cancer Sci
Specialty Oncology
Date 2013 Nov 29
PMID 24283360
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Gastric cancer (GC) is one of the most common malignancies worldwide. In particular, scirrhous type GC is highly metastatic and is characterized clinically by rapid disease progression and poor prognosis. MicroRNAs (miRNAs) play crucial roles in cancer development and progression. In the present study, we identified several miRNAs that are expressed at higher levels in scirrhous type GC than in non-scirrhous type GC by miRNA microarray analysis. Among these, microRNA-143 (miR-143) expression was higher in scirrhous type GC than in non-scirrhous types of GC. In situ hybridization and quantitative RT-PCR analysis showed that miR-143 is expressed by stromal fibroblasts but not by cancer cells. In stromal cells, miR-143 enhanced collagen type III expression in normal gastric fibroblasts and cancer-associated fibroblasts through activation of transforming growth factor-β)/SMAD signaling. Furthermore, high miR-143 expression in GC was associated with worse cancer-specific mortality (P = 0.0141). Multivariate analysis revealed that miR-143 was an independent prognostic factor. Treatment of GC cell lines with 5-aza-2'-deoxycytidine restored the expression of miR-143, and precursor miR-143 caused the inhibition of cancer cell invasion. These data suggest that miR-143 regulates fibrosis of scirrhous type GC through induction of collagen expression in stromal fibroblasts and that miR-143 expression serves as a prognostic marker of GC.

Citing Articles

Targeting MetaLnc9/miR-143/FSCN1 axis inhibits oxidative stress and myofibroblast transdifferentiation in oral submucous fibrosis.

Lu M, Hsieh P, Chao S, Fang C, Ohiro Y, Liao Y J Dent Sci. 2024; 19(3):1416-1425.

PMID: 39035266 PMC: 11259661. DOI: 10.1016/j.jds.2024.04.008.


Equine mesenchymal stem cell derived extracellular vesicle immunopathology biomarker discovery.

Reynolds D, Vallapureddy P, Morales R, Oh D, Pan M, Chintapula U J Extracell Biol. 2024; 2(6):e89.

PMID: 38938916 PMC: 11080797. DOI: 10.1002/jex2.89.


Improving targeted small molecule drugs to overcome chemotherapy resistance.

Rismanbaf A Cancer Rep (Hoboken). 2023; 7(1):e1945.

PMID: 37994401 PMC: 10809209. DOI: 10.1002/cnr2.1945.


The Genomic Signatures of Linitis Plastica Signal the Entrance into a New Era: Novel Approaches for Diagnosis and Treatment.

Christodoulidis G, Koumarelas K, Kouliou M, Samara M, Thodou E, Zacharoulis D Int J Mol Sci. 2023; 24(19).

PMID: 37834127 PMC: 10572839. DOI: 10.3390/ijms241914680.


A novel STAT3/ NFκB p50 axis regulates stromal-KDM2A to promote M2 macrophage-mediated chemoresistance in breast cancer.

Chen J, Teng Y, Chen C, Chen J Cancer Cell Int. 2023; 23(1):237.

PMID: 37821959 PMC: 10568766. DOI: 10.1186/s12935-023-03088-1.


References
1.
Derynck R, Zhang Y . Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425(6958):577-84. DOI: 10.1038/nature02006. View

2.
Jain R . Barriers to drug delivery in solid tumors. Sci Am. 1994; 271(1):58-65. DOI: 10.1038/scientificamerican0794-58. View

3.
Otsuji E, Kuriu Y, Okamoto K, Ochiai T, Ichikawa D, Hagiwara A . Outcome of surgical treatment for patients with scirrhous carcinoma of the stomach. Am J Surg. 2004; 188(3):327-32. DOI: 10.1016/j.amjsurg.2004.06.010. View

4.
Heldin C, Rubin K, Pietras K, Ostman A . High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer. 2004; 4(10):806-13. DOI: 10.1038/nrc1456. View

5.
Esquela-Kerscher A, Slack F . Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6(4):259-69. DOI: 10.1038/nrc1840. View